VKTXViking Therapeutics, Inc.
Pharmaceutical Preparations
- Revenue
- $0
- Operating margin
- —
- EBITDA
- −$393M
- 161% YoY
- Market cap
- $3.5B
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- 0.9
- mentions per 10K words
Takeover score 3 of 13
Fixable underperformance 1 of 7
- TSR below peersNo—3+ of last 5 years
- High CEO pay despite TSRNo—Median CEO pay ≥ $15M while TSR trails
- Earnings not backed by cashNo—Cash flow under 80% of net income
- Dilutive SBCNo—Over 10% of revenue
- Payouts exceed cash flowNo-2% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyNo—Over 40% of assets
- Shareholder dissentYes51% lowest supportAny vote under 80% support
Buyer economics 1 of 4
- Low revenue per employeeNo—Bottom quartile of its SIC industry
- Quiet on AINo0.9 per 10K words · 31st pctBottom quartile of AI mentions in 10-Ks
- Net cashNo—More cash than debt, positive EBITDA
- Buyout-sizedYes$3.5B market capMarket cap $500M–$5B
Catalysts 1 of 2
- Active 13DNo0 filingsActive-intent 13D in 18 months
- Net insider sellingYes−$18M netNet sales over $10M in 12 months
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | |
| Operating income | −$56M | −$70M | −$101M | −$151M | −$393M | 161% |
| Net income | −$55M | −$69M | −$86M | −$110M | −$360M | 227% |
| Operating cash flow | −$48M | −$48M | −$73M | −$88M | −$279M | 217% |
| Stock-based comp | $6M | $9M | $17M | $30M | $41M | 37% |
| Buybacks | — | $7M | — | — | — |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $150K · 1
- Open-market sells, 12 mo
- $18M · 16
- Net
- −$18M
Pay vs performance
No pay-versus-performance disclosure yet.